Celera acquires Berkeley HeartLab

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Celera, a molecular diagnostics company, has completed the acquisition of Berkeley HeartLab (BHL), a Burlingame, Calif.-based company that provides LDL and HDL tests as well as other tests associated with cardiovascular disease, for approximately $195 million in cash.

BHL has approximately 300 employees including 110 laboratory personnel and about 80 field-based sales representatives and clinical educators, and will be operated as a business unit of Celera, according to Alameda, Calif.-based Celera.